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Summnry-In three experiments, rats were injected once daily with 5.0 mg/kg apomorphine or vehicle and
tested for locomotor activity for 10-14 days. In each experiment, apomorphine produced behavioral
sensitization, characterized by a progressively greater increase in locomotor activity with each succeeding
injection. On day 11 of testing, in an experiment designed to assess the synthesis of dopamine (DA), rats
were injected with 5.0 mg/kg apomorphine or vehicle, followed by 100 mg/kg NSD-1015, an inhibitor of
the enzyme /-aromatic amino acid decarboxylase. After administration of NSD-1015, concentrations of
dihydroxyphenylalanine (DOPA) were determined in striatal and mesolimbic tissues by high performance
liquid chromatography (HPLC) with electrochemical detection. The results revealed a significant decrease
in accumulation of DOPA in both striatal and mesolimbic tissue after acute treatment with apomorphine.
More important, chronic treatment with apomorphine prodiJced a significant increase in accumulation of
DOPA in both areas. In subsequent experiments, rats on day 14 of testing were sacrificed for determination
of levels of DA, 3,4-dihydroxyphenylacetic acid (DOPAC) or specific binding of [3H]spiperone in the
striatum and mesolimbic region. Although levels of DOPAC were significantly reduced in the regions of
the brain after an acute injection of apomorphine, chronic treatment with apomorphine did not
significantly affect levels of DA, DOPAC or specific binding of [3H]spiperone. These findings suggest that
the development of behavioral sensitization to apornorphine may be related to an alteration in the
synthesis of DA·.
Key words-apomorphine, behaviOral sensitization, dopamine, striatum, mesolimbic system.

Drugs that act by directly or indirectly stimulating
central dopamine (DA) systems, often produce progressively greater behavioral responses with repeated
administration. This behavioral sensitization effect
has been demonstrated using several drugs that act as
direct or indirect DA agonists, including cocaine,
amphetamine and apomorphine (Castro, Abreu,

Each of the sensitization-producing DA agonists
has a different mechanism of action on central dopaminergic transmission. Cocaine, _for example, en-

Calzadilla and Rodriguez, 1985; Kalivas, Duffy,
DuMars and Skinner, 1988; Mattingly, Gotsick and

DA (Zetterstrom, Sharp, Marsden and Ungerstedt,

hances the activity of DA indirectly by inhibition of
the uptake of dopamine (Zahniser et al., 1988).
Amphetamine is also an indirect-acting DA agonist,
producing its effects primarily by inducing release of
1983). In contrast, apomorphine is a direct-acting DA
receptor agonist (Creese, Hamblin, Leff and Sibley,

Salamanca, 1988; Reith, 1986; Robinson and Becker,
1986; Zahniser, Peris, Dwoskin, Curella, Yasuda,

1983). The differential behavioral effects of DA ago-

O'Keefe and Boyson, 1988). While the acute

nists, with chronic administration, may be related to
the differential mechanisms of action of each of these
drugs on DA neurotransmission.
Much attention has been given in recent years to
the neuropharmacological correlates of cocaine- and
amphetamine-induced behavioral sensitization (see

behavioral effects of DA agonists are similar,
significant behavioral differenc_es exist among these
drugs in the development of behavioral sensitization.
For example, chronic administration of amphetamine
enhances amphetamine-induced stereotypy (i.e.
repetitive sniffing, head and limb movements) and

Robinson and Becker, 1986; Zahniser et al., 1988 for

locomotor activity (Robinson and Becker, 1986).

reviews). Consequently, the effects of amphetamine
and cocaine on various indices of DA function are
well characterized. In contrast, less is ~nown of the
neuropharmacological effects of chronic administration of apomorphine. Available evidence suggests
that chronic treatment with apomorphine does not

Similarly, chronic administration of cocaine enhances
cocaine-induced stereotypy and locomotor activity

(Kalivas et al., 1988; Reith, 1986). In contrast,
chronic administration of apomorphine enhances

locomotor activity but not stereotypy (Mattingly,
Gotsick and Marin, 1988).

affect the binding of [3H]spiperone in the striatum of
the mouse (Riffee, Wilcox, Vaughn and Smith, \982)
but the effect of chronic treatment with apomorP,hine

•To whom correspondence should be addressed.
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on binding sites for DA in other pathways (e.g,
mesolimbic) has not been determined. Similarly, the
effect of chronic treatment with apomorphine on the
synthesis and metabolism of DA in various DA
terminal fields is unknown. The purpose of the
present study, therefore, was to determine the effects
of chronic treatment with apomorphine on various
indices of DA function in striatal and mesolimbic
terminal fields. In three experiments, rats were injected daily with a large dose of apomorphine to
induce sensitization, using locomotor activity as a
behavioral measure. In the first experiment, the synthesis of DA in anterior striatal and mesolimbic tissue
was assessed after acute and chronic treatment with
apomorphine by measuring the accumulation of dihydroxyphenylalanine (DOPA), after administration
of an /-aromatic amino acid decarboxylase inhibitor.
In a second experiment, changes in levels of DA and
3,4-dihydroxyphenylacetic acid (DOPAC) were
measured after behavioral testing. Finally, a third
experiment assessed the binding density of
[3H]spiperone in striatal and mesolimbic regions after
acute and chronic treatment with apomorphine.
METHODS

Subjects

Male Wistar albino rats, experimentally naive and
weighing between 250-300 g, were used ih each experiment. All rats were housed individually, maintained
on ad libitum food and water and a 12-hr lig~t/dark
cycle was held constant throughout the study. All
behavioral testing was conducted during the light
phase of the cycle.
Activity testing apparatus

Measures of activity were taken in two BRS/
Lehigh Valley cylindrical activity drums (Model 145·
03), which were 60 cm in diameter and 43 cm high.
The interior of the drums was painted fiat blii.ck and
the floor was made of 4 cm diamond wire mesh. Each
drum was located in a separate experimental cubicle
that was kept totally dark throughout testing. Each
drum was equipped with two banks of three infrared
photocells mounted of the outside of the drums. The
photocells were approximately 12 cm apart and
2.5 cm above the floor of the drum. The banks of
photocells were connected to electromechanical
counters, in an adjacent control room, by way of
back-path eliminator diodes. Movement of the rat
through a photocell beam sent a single pulse to the
counters. Simultaneous pulses (i.e. pulses spaced less
than 0.05 sec apart), such as might occur when two
beams were broken near their intersection, were
recorded as a single count by this method. Thus,
activity was defined as the cumulative number of
interruptions of photobeams per unit time.
Locomotor activity testing and dissections

At the beginning of each experiment, the rats were

randomly assigned to either the apomorphine- or
vehicle-pretreatment condition. The rats received 13
daily subcutaneous injections of 5.0 mg/kg apomorphine hydrochloride (Sigma) or vehicle (0.001 N HCI),
except in the experiment assessing the synthesis of
DA in which only 10 daily injections were administered. The dose injected was calculated, based on the
weight of the salt of the drug and the volume of
administration was held constant at 0.5 ml/kg. The
dose of apomorphine (5.0 mg/kg) and the length of
administration (lCl-13 days) were chosen, based on a
previous study, which demonstrated maximum
locomotor sensitization using these parameters
(Mattingly et al., 1988).
During the chronic pretreatment sessions, each rat
was removed from its home cage, weighed and then
injected with either apomorphine or vehicle. After the
injection, the rats were returned to their home cage.
Fifteen minutes later, the rats were placed in the
activity drums and activity counts were recorded at
10-min intervals for a total of 20 min. All rats were
tested with an approximately 24-hr interval between
each activity test session.
During the final session of each experiment, onehalf of the rats in each chronic pretreatment condition were randomly assigned to either the
apomorphine- or vehicle-acute-challenge condition.
During the drug challenge session of the DA synthesis experiment, the rats were injected with either
5.0 mg/kg apomorphine or vehicle. Fifteen minutes
after the injection, the animals received the
/-aromatic amino acid decarboxylase inibitor, NSD1015 (M-hydroxybenzylhydrazine dihydrochloride,
100 mg/kg, i.p., Sigma) and were sacrificed 30 min
later by rapid decapitation. The brains were rapidly
removed and placed on a ice-cold dissection plate.
During the challenge session with drug, of the DA
metabolite experiment, activity measures were taken
in order to assess the effects of acute administration
of apomorphine on locomotor activity and levels of
metabolites. After activity testing (20 min), the ani·mals were then sacrificed and ihe brains removed as
in the DA synthesis experiment. During the drug
challenge session of the binding experiment, each rat
was injected with either 5.0 mg/kg apomorphine or
vehicle and returned to its home cage. Fifteen minutes
later, each animal was sacrificed by rapid decapitation. In all the experiments, samples of striatal
(anterior to optic chiasm) and mesolimbic (nucleus
accumbens septi and olfactory tubercles) tissue were
dissected, frozen on dry-ice and then stored at - 70°C
for the assay. Tissue samples used for the assays of
synthesis and metabolites of DA were placed in
15 vols of 0.1 N HCI04 before freezing.
Determination of DOPA, DA and DOPAC

Tissue samples were thawed and sonicated with a
microhomogenizer (Vibracell, setting 80). The homogenate was centrifuged at 40,000 g for 10 min at 4°C.
Twenty microliters of supernatant were assayed for
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DOPA, DA and DOPAC using a high-pressure liquid
chromatograph, with an electrochemical detector
(Bioanalytical Systems, LC-304T) and a temperature-controlled (25°C) 5 µm column (Bioanalytical
Systems, PN 6207). The mobile phase for determination of DOPA was prepared as described by Sparks
and Slevin (1985). The mobile phase for determination of DA and DOPAC was prepared as described
by Mayer and Shoup (1983). External standards for
DOPA, DA and DOPAC (Sigma) were assayed daily.
Receptor binding

';
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Sections of brain were thawed and homogenized,
using a Brinkmann Polytron (5 sec, setting 6) in
100 vols of ice-cold 50 mM Tris buffer (pH 7.4 at
37°C). The homogenate was then centrifuged at
40,000 g for I 0 min at 4°C. The supernatant was
discarded and the pellet resuspended and briefly
sonicated (Vibracell, setting 80) in an equal volume of
Tris buffer. This washing procedure was repeated
twice and the tissue was resuspended in a final 200
vols of ice-cold 50 mM Tris buffer, containing
120 mM NaCl, 5 mM KCl, 2 mM CaCl,, 1 mM
MgS04 , IOµM pargyline and 0.1% ascorbic acid
(pH 7.4 at 37°C). Tissue homogenates were pre-incubated at 37°C for IO min and then placed on ice. After
pre-incubation, 950 µl of tissue sample were incu-,
bated at 37°C for 15 min with 0.4 nM [3H]spiperone
(New England Nuclear, specific activity=
26.8 Ci/mmol) and either 1.0 µM haloperidol or
an equal volume of the Tris buffer with ions. In
previous experiments, it was found that 1.0 µM
haloperidol displaced 0.4 nM [m]spiperone from
fresh striatum of the rat, similar to 1.0 µM ( + )butaclamol (unpublished observations). Fifty µM
ketanserin (Janssen Pharmaceuticals) was added to
all tubes to displace [3H]spiperone from 5-hydroxytryptamine2 receptors (List and Seeman, 1981). Saturation studies were carried out in striatal tissues, using
six concentrations of rH]spiperone, ranging from 0.02
to 1.0 nM. The final incubation volume was 1.0 ml.
After incubation, the samples were returned to ice
and filtered (Whatman GF/B glass fiber filters) under
vacuum pressure. The filters were washed of unbound
3
[ H]spiperone with two 5 ml vols of ice-cold Tris
buffer (no ions) and placed in glass vials with 8.0 ml
scintillation cocktail (Research Products Intl. 3a70B).
The radioactivity was measured by liquid scintillation
spectrometry, using a Packard 3380, with approximately 25o/o counting efficiency. Specific binding was
defined as the difference in bound radioactivity,
obtained in the presence and absence of haloperidol.
All samples were assayed in duplicate.
Analysis of data

The pretreatment activity data were analyzed by
mixed factor analysis of variance (ANOVA) with
chronic pretreatment drug and acute challenge drug,
as between groups factors and session as a repeated
measure. The challenge treatment activity data were
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analyzed by I-tests, using the Scheffe procedure
(family-wise error controlled at 0.05). Separate 2 x 2
factorial ANOV As were used to analyze levels of
DOPA, DA, DOPAC and the binding of
[3H]spiperone for each region of the brain.
Saturation isotherms were obtained from
duplicated pooled tissue (i.e. n = 2), consequently,
statistical comparisons between groups were not
carried out. The K 0 and BmaY.. values were derive9 by
non-linear regression analysis, using the LIGAND
software package (Munson and Rodbard, 1980).
When a single concentration of radio ligand was used,
the B~Ja.7,. value was estimated using the equation:
Bm,. = B(L

+ K 0 )/L

In the equation, B is the amount of [3H]spiperone
specifically bound ~t radioligand concentration L
(Boyson, McGonigle and Molinoff, 1986). The K 0
values used in the equation were those obtained from
the anterior striatum saturation experiments .
RESULTS

Locomotor activity

Figure I presents the mean activity counts of the
four groups for the 13 chronic pretreatment activity
test sessions for the receptor binding experiment. The
results from the chronic pretreatment sessions of the
other two experiments showed similar results to
the chronic pretreatment sessions of the binding
experiment (data not shown).
As may be seen in Figure I, the four groups·
displayed comparable activity levels during the first
session, but significant differences emerged with repeated testing. Chronic administration of apomorphine produced a progressively larger increase in
activity with each succeeding injection (P < 0.05,
ANOV A). This increase was asymptotic by approximately the tenth session. In contrast, the vehicletreated groups revealed no significant change in
activity with the sessions. Also, the challenge drug
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Fig. 1. Mean activity counts per 10 min block, for groups
receiving 5.0 mg/kg apomorphine or vehicle, subdivided by
challenge group for 13 sessions. Treatments are represented

by chronically-administered pretreatment drug-acutely-administered challenge drug. Drug or vehicle was administered
15 min before each 20 min session.
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morphine. In both striatal and mesoHmbic tissues,
acute administration of apomorphine decreased .the
accumulation of DOPA (P < 0.05, main effect of
acute administration of drug, ANOVA). More
important, chronic treatment with apomorphine
resulted in a significant increase in the accumulation
of DOPA in both_ the striatal and mesolimbic tissues
compared to chronic treatment with vehicle
(P < 0.05, main effect of chronic administration of
drug, ANOV A). There was no significant interaction
between chronic and acute treatment with drug in
either region.

AC\ITE

•

CJ l\Oomorphlne

1200

KS8 Vehicle

900

600

Apomorphine

Veh!cle

CHRONIC

Fig. 2. Mean actiVity counts per 10 min block on day 14
(acute challenge session) of testing. The dose of apomorphine used was 5.0 mg/kg. Drug or vehicle was administered
15min before each 20min session. *P<0.05 vs chronic
apoffiorj,hine-acute vehicle challenge and the two chronic
vehicle groups (I-test, Schetre•s procedure).

Dopamine and DOPAC

Table 2 presents the mean concentrations of DA
and DOPAC. Chronic .treatment with apomorphine
did not produce significant changes in levels of DA
in either the striatal or mesolimbic tissues. Similarly,
levels of DOPAC in both striatal and mesolimbic
tissues were not affected by chronic treatment with
apomorphine. In contrast, acute challenge inj~ctions
of apomorphine resulted in a significant decrease
in concentrations. of DOPAC in both regions of
the brain (P < 0.05). This apomorphine-induced
decrease in levels of DOPAC, however, did not differ
for rats pretreated chronicaliy with apomorphine or
vehicle.

groups displayed no significant differences during the
pretreatment sessions, indicating that no inherent
differences existed prior to the challenge test.
Figure 2 presents the activity data from day 14 of
the experiment on metabolites of DA. As may be seen
from the figure, animals pretreated with apomorphine and challenged with apomorphine displayed
higher levels of activity than the .other three groups
(P < 0.05. Schefft\'s test). The latter three groups were
not significantly different from one another in levels
of activity.

•

Receptor binding

Table 3 presents the mean specific binding of
[3H]spiperone and estimates of Bmax in striatal and
mesolimbic tissue. As may be seen in Table 3., chronic
treatment with apomorphine and acute challenge

Accumulation of DOPA

Table I presents mean accumulatiori values for
DOPA after chronic and acute treatment with apo-

Table I. Changes in accumulation of DOPA induced by acute and chronic administration of
apomorphine after inhibition of DOPA decarboxylase by NSD-1015 in rats (n = 8 per group)
Mean µg DOPA/g wet tissue weight± SEM
Treatment (chroriic-acute)
Apomorphine-Apomorphine
Vehicle-Apomorphine
Apomcirphine-Vehicle
Vehicle-Vehicle

Anterior striatum

Mesolimbic region

1.46 ± 0.12•.b
1.18 ± 0.11 1
4.14± 0.29b
3.38 ± 0.23

1.85±0.19a,b
1.75 ± 0.22•
3.04 ± 0.15b
2.41 ±0.12

"Acutely-treated apomorphine groups (Apomorphine-Apomorphine and VehicleApomorphine combined) were significantly different from acutely-treated vehicle groups
(Apomorphine-Vehicle and Vehicle-Vehicle combined), analysis of variance, main effect of
acute treatment with drug, P < 0.05.
bChronically-treated apomorphine groups (Apomorphine-ApomOrphine and ApomorphineVehicle combined) were significantly different from chronically-treated vehicle groups
(Vehicle-Apomorphine and Vehicle-Vehicle combined), analysis of variance, main effect of
chronic treatment with drug, P < 0.05.
Table 2. Mean values for DA and DOPAC after acute and chronic treatment with apomorphine in
rats (n = 9-10 per group)
Mean µg/g wet tissue weight± SEM
Anterior striatum
Treatment (chronic-acute)
Apomorphine-Apomorphine
Vehicle-Apomorphine
Apomorphine-Vehicle
Vehicle-Vehicle

DA

16.3 ±
15.5 ±
15.5 ±
15.4 ±

1.07
1.09

1.42
1.22

Mesolimbic region

DOPAC

DA

DOPAC

2.2±0.15"
2.4±0.10"
3.5 ±0.35
3.3 ±0.32

6.1±0.43
6.2 ± 0.10
6.2 ± 0.21
6.2 ± 0.26

0.9 ± 0.07"
I.I ±0.07"
1.6±0.10
1.6±0.08

•Acutely-treated apomorphine groUps (Apomorphine-Apomorphine and Vehicle-Aponnorphine
combined) were significantly different from acutely-treated vehicle groups (ApomorphineVehicle and Vehicle-Vehicle combined), analysis of variance, main effect of acute treatment with
drug, P < 0.05.
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195

Apomorphine, neurochemistry and activity
Table 3. Specific binding of 0.4 nM [3H]spiperone after acute and chronic treatment with
apomorphine in rats (n = 10 per group)
Mean fmol/mg wet tissue weight± SEM
Anterior striatum
Treatment (chronic..:.acute)
Apomorphine-Apomorphine
Vehicle-Apomorphine
Apomorphine-Vehicle
Vehicle-Vehicle

Bound
15.9±0.7
15.5 ± 0.4
19.0 ± 0.6
17.9 ± 0.6

Mesolimbic region

B=,

Bound

Bmu

21.9 ± 1.0
21.7±0.6
24.2 ±0.8
23.3 ±0.8

5.1±1.2
5.4 ± 1.2
5.0 ± 1.5
5.7 ± 1.8

7.0± 1.6
7.6± 1.7
6.4 ± 1.9
7.4 ±2.3

+ K0 )/l where B.is specific [3HJspiperone
bound and Lis the concentration of radioligand (Boyson et al., 1986). K0 viilues were obtained
from saturation isotherms in anterior striatum.

Bm .. values were estimated by the equation Bm .. = B(l

.'

with apomorphine did not significantly affect the
binding of [3H]spiperone in either the striatal or
mesolimbic tissues (P > 0.05 in each case).
Figure 3 presents saturation curves, Scatchard
plots (inset), K 0 and Bmax values for striatal tissue of
rats treated chronically with apomorphine. Scatchard
plots were linear and subsequent LIGAND analyses
indicated that the curves were best fit fed to a one-site
model. Thus, within the concentration range used,
3
[ H]spiperone labelled a homogeneous population of
22,-~~~~~~~~~~~~~~~----,
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Fig. 3. Saturation curves and Scatchard plots (inset) for the
binding of[3H]spiperone to anterior striatum of the rat. The
top graph represents groups receiving a challenge of
5.0 mg/kg apomorphine on session 14 after chronic pretreatment with 5.0 mg/kg apomorphine or vehicle. The bottom
graph represents groups receiving challenge with vehicle on
session 14 after chronic pretreatment with 5.0 mg/kg
apomorphine or vehicle. The KD and Bma~ values are as
KD = 0.15 nM;
follows:
Apomorphine-Apomorphine,
Brrw. = 22.39 fmol/mg wet tissue weight; Vehicle-Apornorphine, KD=0.16nM, Bmv..=20.72fmol/mg wet. weight;
Apomorphine-Vehicle, K 0 = 0.11 nM, Bma~ = 20.8 fmol/mg
wet weight; Vehicle-Vehicle, KD = 0.12 nM, Bmax =

21.96 fmol/mg wet weight.
NP 30/2-F

binding sites. No differences between chronically
treated apomorphine and vehicle groups were apparent in the saturation isotherms, obtained after an
acute challenge with either apomorphine (Fig. 3, top
panel) or vehicle (Fig. 3, bottom panel).
DISCUSSION

Consistent with previous studies (e.g. Castro et al.,
1985; Mattingly et al., 1988), the present results
clearly demonstrated the development of sensitization to apomorpine in rats, using locomotor activity
as a behavioral measure. Moreover, as in a previous
study (Mattingly et al., 1988), no evidence of conditioned hyperactivity was observed in the present
study, when sensitized rats were injected with vehicle
rather than apomorphine. This latter finding suggests
that the development of behavioral sensitization to
apomorphine cannot be explained by conditioning
factors alone. It should be noted, however, that
although conditioned hyperactivity has not been observed in rats sensitized to apomorphine, the potential involvement of conditioning factors cannot be
dismissed since drug-associated contextual stimuli
have been shown to facilitate the development of
behavioral sensitization to apomorphine (Mattingly
and Gotsick, 1989).
The present study found that the accumulation of
DOPA was increased after chronic treatment with
apomorphine in both the striatum and the mesolimbic region. One possible interpretation of the observed increase in synthesis of DA is that chronic
administration of apomorphine may produce subsensitivity of autoreceptors. Autoreceptors for DA appear to be part of a negative feedback loop which
regulates the firing rate of DA neurons, as well as the
synthesis and release of DA (Roth, 1984). By inducing subsensitivity of autoreceptors, chronic administration of apomorphine·may enhance the basal firing
rate, release and synthesis of DA. In support of this
subsensitivity hypothesis, the acute apomorphineinduced inhibition of the.firing rate of DA neurons in
the striatum and ·substantia nigra has. been shown
to be significantly attenuated chronic treatment
with apomorphine in large doses (Rebec and: Lee,
1982).
'
In contrast, behavioral experiments utilizing administration of small doses ofapomorphine have not
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demonstrated results consistent with the idea of an
apomorphine-induced decrease in the sensitivity of
autoreceptors. Administration of small doses of
apomorphine appears to decrease locomotor activity,

an effect proposed to be autoreceptor-specific
(Skirboll, Grace and Bunney, 1979). Studies assessing

the effects of chronic administration of small doses
of apomorphine have demonstrated that both the
ability of small doses of apomorphine to attenuate
amphetamine-induced sensitization (Riffee, Wanek
and Wilcox, 1987) and the ability of apomorphine to
decrease locomotor activity (Mattingly et al., 1988)
does not change with repeated injections. Likewise, in

the present study, the decrease in levels of DOPAC,
observed after acute treatment \Vith apomorphine
was not altered by chronic treatment with
apomorphine. The acute decrease in levels of
DOPAC is consistent with other reports (e.g.
Bannon and Roth, 1983; Westrink and Korf, 1976)
and is thought to reflect stimulation of DA

autoreceptors. Together, these behavioral and
neurochemical results suggest that the autoreceptors
maintain their sensitivity. An alternative explanation
would be that a subset of autoreceptors, modulating
synthesis of DA, as opposed to autoreceptors
modulating release of DA, may be preferenlially
affected by chronic administration of apomorphine
(Wolf and Roth, 1987). However, it is also possible

that chronic administration of apomorphine
may produce a significant increase in synthesis
of DA, independent of stimulation of autoreceptors,
as recent reports have suggested that apomorphine
may have a direct action upon tyrosine hydroxylase (cf. Riffee et al., 1987; Saller and Salama,
1986).

-

The density of binding sites for DA, as measured
by specific binding of (3H]spiperone in striatal and

mesolimbic tissue, was not significantly affected by
chronic administration of apomorphine. Consistent
with this result, Riffee et al. (1982) reported no
significant changes in the binding of [3H]spiperone in

striatum of the mouse after chronic treatment with
large doses of apomorphine. Likewise, chronic treatment with amphetamine and cocaine do not appear
to reliably alter the density of binding sites for DA
(see Robinson and Becker, 1986; Zahniser et al.,
1988). Thus, apomorphine-induced sensitization, like

amphetamine- and cocaine-induced sensitization,
does not appear to be mediated by alterations in the
number of postsynaptic binding sites for DA. It is, of
course, possible that chronic treatment with apomorphine may result in significant changes in the D 1
receptors subtype, which may be related to the devel-

opment of behavioral sensitization. Apomorphine is
reported to be a partial agonist at D 1 sites, as well as
a full agonist at D 2 sites (Creese et al., 1983). Unfortunately, the potential involvement ofD 1 sites cannot
be determined from the present results because both
spiperone and haloperidol bind with high affinity

primarily to D 2 receptors.
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